Form 4 for ANRO Alto Neuroscience, Inc.
Accepted 2024-02-07 00:00:00 ET · period of report 2024-02-06 · accession 0001415889-24-002934 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-07 | 2024-02-06 | ANRO | Etkin Amit | Pres AND CEO, Dir | P - Purchase | $16.00 | +3,125 | 1.21M | +0.3% | +$50.0K |
| D | 2024-02-07 | 2024-02-06 | ANRO | Etkin Amit | Pres AND CEO, Dir | C - Cnv Deriv | — | +11.8K | 1.20M | +1.0% | — |
| D | 2024-02-07 | 2024-02-06 | ANRO | Etkin Amit | Pres AND CEO, Dir | C - Cnv Deriv | $0.00 | -25.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-06 | P | A | 3,125 | $16.00 | 1,205,465 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-06 | C | A | 11,777 | — | 1,202,340 | D | — | — | (F1) Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. |
| 3 | Derivative | Series B Preferred Stock | 2024-02-06 | C | D | 25,000 | $0.00 | 0 | D | — · — to — | 11,777 Common Stock | (F1) Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. |